

ViiV HEALTHCARE PRESENTS: An Interactive Educational Event for RUKOBIA (fostemsavir)

RUKOBIA: MDR HIV and Constructing the Regimen

INDICATION

RUKOBIA, in combination with other antiretrovirals (ARVs), is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.

PRESENTED BY:

Zandraetta Tims-Cook, MD, MPH

Faebris Medical

Dr. Zandraetta Tims-Cook is the Medical Director of Faebris Medical & Community Education, an infectious diseases practice, and an Associate Clinical Professor of Medicine at Wellstar Atlanta Medical Center in Atlanta. Dr. Tims-Cook is active in HIV research. Her interests include HIV health disparities, particularly disparities seen among women. She is also involved in community outreach efforts in HIV education and is a board-certified Infectious Disease Specialist. Dr. Zandraetta Tims-Cook earned her undergraduate degree at Spelman College and her Master of Public Health at Columbia University. She received her medical degree from Cornell Medical College in 2005.



Location

Bianca's Restaurant - Albany
2401 Dawson Road Suite T1
Albany, Georgia 31707

Thursday, January 15, 2026

6:30 PM - EST

Speakers are employed or compensated by ViiV Healthcare.

To RSVP, Contact Your ViiV Representative

Sandy Siemon

sandy.siemon@syneoshealth.com

4079291877



To register for this program, scan the QR code or visit the following link: <https://myattendeeresource.com/gsk/260115-gsk-114268>

IMPORTANT SAFETY INFORMATION

Contraindications

- Do not use in patients with previous hypersensitivity to fostemsavir or any of the components of RUKOBIA.
- Do not use RUKOBIA in patients receiving strong cytochrome P450 (CYP)3A inducers, including but not limited to enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, and St John's wort (*Hypericum perforatum*).

Please see additional Important Safety Information for RUKOBIA on reverse.

Please see accompanying full [Prescribing Information](#) for RUKOBIA.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and precautions

Immune Reconstitution Syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported with the use of RUKOBIA.

QTc Prolongation with Higher than Recommended Dosages: RUKOBIA at 2,400 mg twice daily has been shown to significantly prolong the QTc interval of the electrocardiogram. Use RUKOBIA with caution in patients with a history of QTc interval prolongation or in patients with relevant pre-existing cardiac disease or who are taking drugs with a known risk of Torsade de Pointes. Elderly patients may be more susceptible to drug-induced QT interval prolongation.

Elevations in Hepatic Transaminases in Patients with Hepatitis B or C Virus Co-infection:

- Monitoring of liver chemistries is recommended in patients with hepatitis B and/or C co-infection.
- Diligence should be applied in initiating or maintaining effective hepatitis B therapy when starting RUKOBIA in patients co-infected with hepatitis B.

Adverse Reactions or Loss of Virologic Response Due to Drug Interactions with concomitant use of RUKOBIA and other drugs may occur (see Contraindications and Drug Interactions).

Adverse reactions

- The most common adverse reaction (all grades, randomized cohort) observed in $\geq 5\%$ of subjects was nausea (10%).
- 81% of adverse reactions reported with RUKOBIA were mild or moderate in severity.

Drug interactions

- See the full Prescribing Information for RUKOBIA for a complete list of significant drug interactions.
- Temsavir may increase plasma concentrations of grazoprevir and voxilaprevir. Use an alternative hepatitis C virus regimen if possible.
- Use the lowest possible starting dose for statins and monitor for statin-associated adverse events.
- Patients receiving RUKOBIA should not take doses of estrogen-based therapies, including oral contraceptives, that contain more than 30 mcg/day of ethinyl estradiol. Caution is advised particularly in patients with additional risk factors for thromboembolic events.

Use in specific populations

- **Pregnancy:** There are insufficient human data on the use of RUKOBIA during pregnancy to definitively assess a drug-associated risk for birth defects and miscarriage. An Antiretroviral Pregnancy Registry has been established.
- **Lactation:** Potential risks of breastfeeding include HIV-1 transmission, developing viral resistance in HIV-positive infants, and adverse reactions in a breastfed infant.

This is a promotional education program sponsored by ViiV Healthcare (VH). VH is committed to complying with applicable federal, state, and local laws, industry codes, and employer policies relating to the provision of meals in conjunction with promotional education programs. As a result, VH identifies whether healthcare professional attendees are eligible to receive meals before programs take place. To facilitate this process, all individuals who wish to attend this program must RSVP in advance. Note that VH may publicly disclose information regarding the monetary value of meals and related expenses provided to you as an attendee of this program.

Please see additional Important Safety Information for RUKOBIA on reverse.
Please see accompanying full [Prescribing Information](#) for RUKOBIA.



For US Healthcare Professionals only.
Trademarks are owned by or licensed to the ViiV Healthcare group of companies.
©2024 ViiV Healthcare or licensor.
PMUS-FSTLBND240017 July 2024
Produced in USA.

